Related Articles
VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form
Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure
Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells
Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice
Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis